Western Suburbs Cancer Clinical Trials

Cancer Clinical Trials

Western Suburbs Cancer Clinical Trials

If you or someone you love is facing cancer, clinical trials may provide an alternative. Northwestern Medicine offers clinical studies right in your community for a wide variety of types and stages of cancer. These research studies are designed to test new ways to diagnose, treat and prevent cancer, as well as to manage symptoms and side effects of the disease.

Clinical trials have played an important role in the fight against cancer. They are the only scientific way to prove whether a new treatment works better than current treatments. Most of the approaches that doctors use to treat cancer today would never have become available without clinical trials.

Current Central DuPage Hospital, Delnor Hospital and Kishwaukee Hospital Cancer Clinical Trials

Currently, there are a wide variety of oncology clinical trials available through physicians on the medical staffs of Northwestern Medicine Central DuPage Hospital, Northwestern Medicine Delnor Hospital and Northwestern Medicine Kishwaukee Hospital. For ease of searching, the trials are sorted into the following categories:

  • Bladder
  • Blood, Bone & Tissue
  • Brain
  • Breast
  • Colorectal
  • Esophageal
  • Kidney
  • Liver
  • Lung
  • Pancreatic
  • Prostate
  • Women's Reproductive System
  • Other Cancers

If you find a clinical trial that interests you, talk with your physician or call 630.933.6528. TTY 711.

View Trials

  • Bladder Cancer
  • Blood, Bone & Tissue Cancers
  • Brain Tumors
  • Breast Cancer
  • Colon & Colorectal
  • Esophageal Cancer
  • Gallbladder Cancers
  • Kidney Cancers
  • Liver Cancers
  • Lung Cancers
  • Other Cancer Trials
  • Pancreatic Cancers
  • Prostate Cancers
  • Skin Cancers
  • Women's Reproductive System Cancers

Study: A Phase II study of Bladder SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3 Node PosItive BladdeR CancEr (INSPIRE)
Clinical Trial #: EA8185
NCT Number: NCT04216290
Principal Investigator: Dr. David VanderWeele
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Chemoradiotherapy with or w/o Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer.
Clinical Trial #: S1806
NCT Number: NCT03775265
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Clinical Trial #: S1925
NCT Number: NCT04269902
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Clinical Trial #: EAA173
NCT Number: NCT03937635
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Clinical Trial #: N0577
NCT #: NCT00887146
Principal Investigator: Dr. Kumthekar
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A phase 1/1b adaptive dose escalation study of mycophenolate mofetil (MMF) in combination with standard of care for patients with glioblastoma
Clinical Trial #: NU 21C01
NCT#: NCT05236036
Principal Investigator: Dr. Kumthekar
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Clinical Trial #: NRG-BN012
NCT#: NCT05438212
Principal Investigator: Dr. Magill
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Safety and tolerability of MW151 administered with hippocampal avoidant whole brain radiation therapy (HA-WBRT) in patients with brain metastases
Clinical Trial #: MW151-102 ImmunoChem
NCT#: NCT05417282
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Clinical Trial #: NRG-CC009
Principal Investigator: Dr. Sachdev
Contact: Research Office 630.933.7820


Study: A Phase 2, single arm, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma
Clinical Trial #: NU 16C02
NCT#: NCT02847559
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase 1-2 Dose-Escalation and Expansion Study of ST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors
Clinical Trial #: SAPIENCE ST101-101
NCT#: NCT04478279
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: A Phase I study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma
Clinical Trial #: 18-048 BrainUp
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820


Study: A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Clinical Trial #: NRG-BN007
NCT #: NCT04396860
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Clinical Trial #: EAF151 20-062
NCT #: NCT03115333
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Clinical Trial #: NRG-BN009
NCT #: NCT04588246
Principal Investigator: Dr. Gondi 1
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Clinical Trial #: NU18C02
NCT #: NCT04047706
Principal Investigator: Dr. Buerki
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to intermediate Grade Gliomas.
Clinical Trial #: NRG-BN005
NCT #: NCT03180502
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2

Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Clinical Trial #: S1609
NCT #: NCT02834013
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2

Study: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Clinical Trial #: NRG-BN003
NCT #: NCT03180268
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2

Study: A Phase III Clinical Trial Evaluating De-escalation Of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer (DEBRA)
Clinical Trial #: NRG-BR007
NCT #: NCT04852887
Principal Investigator: Dr. Donnelly
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Clinical Trial #: S2007
NCT#: NCT04647916
Principal Investigator: Dr. Ami Shah
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA): A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.
Clinical Trial #: TOL2506 OVELIA 21-041
NCT#: NCT04906395
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE,
Clinical Trial #: EA1183 22-003
NCT#: NCT04316117
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820 

Learn more at Clinicaltrials.gov


Study: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Clinical Trial #: A011801 22-011
NCT#: NCT04457596
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.
Clinical Trial #: NU 15B06
NCT Number: NCT02694809
Principal Investigator: Mary Ahn, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL
Clinical Trial #: RTOG3510/PCORI
NCT Number: NCT02603341
Principal Investigator: Dr. Thukral
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Clinical Trial #: CCTG MA.39
NCT Number: NCT03488693
Principal Investigator: Dr. Thukral
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Clinical Trial #: A021502
NCT Number: NCT02912559
Principal Investigator: Dr. Dawravoo
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Clinical Trial #: NRG GI005
NCT Number: NCT04068103
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Clinical Trial #: NRG-GI008
NCT Number: NCT05174169
Principal Investigator: Dr. Mary Mulcahy
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Clinical Trial #: EA2183
NCT#: NCT04248452
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820


Learn more at Clinicaltrials.gov

Study: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Clinical Trial #: NRG GI006
NCT Number: NCT03801876
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Clinical Trial #: EA2197
NCT#: NCT04559139
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Renal

Study: A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Clinical Trial #: S2200
NCT #: NCT05411081
Principal Investigator: Dr. Shenoy
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)
Clinical Trial #: S1931
NCT Number: NCT04510597
Principal Investigator: Dr. Jeffrey Sosman
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: (PDIGEE) PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer
Clinical Trial #: A031704
NCT Number: NCT03793166
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Clinical Trial #: NRG-GU012
NCT Number: NCT05327686
Principal Investigator: Dr. Sean Sachdev
Contact: Research Office (630) 933-7820

Learn more at Clinicaltrials.gov

Please check back

Study: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Clinical Trial #: EA3191
NCT Number: NCT04671667
Principal Investigator: Dr. Jochen Lorch
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Clinical Trial #: A151216
NCT Number: NCT02194738
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Clinical Trial #: E4512
NCT Number: NCT02201992
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
Clinical Trial #: Protocol RTOG1308
Principal Investigator: Vinai Gondi, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Germ Cell Tumors

Study: A Prospective Observational Cohort Study to Assess mRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Clinical Trial #: S1823
NCT #: NCT04435756
Principal Investigator: Dr. Kundu
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Squamous Cell Carcinoma

Study: A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Clinical Trial #: EA2182
NCT #: NCT04166318
Principal Investigator: Dr. Kircher
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Metastatic Urothelial Carcinoma

Study: A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Clinical Trial #: S1937
NCT #: NCT04579224
Principal Investigator: Dr. Fenton
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Myelodysplastic Syndromes

Study: he National Myelodysplastic Syndromes (MDS) Study
Clinical Trial #: NHLBI-MDS
NCT#: NCT02775383
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Oropharyngeal Cancer

Study: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Clinical Trial #: NRG-HN005
NCT Number: NCT03952585
Principal Investigator: Dr. Gharzai
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Colorectal Cancer

Study: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Clinical Trial #: A221805
NCT Number: NCT04137107
Principal Investigator: Dr. Abad
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Mantle Cell Lymphoma

Study: A randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Clinical Trial #: EA4151
NCT Number: NCT03267433
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Multiple Myeloma

Study: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Clinical Trial #: EAA181
NCT Number: NCT04566328
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Recurrent Tumors Previously Treated with Radiation Therapy

Study: Retreatment of non-CNS solid malignancies. Treatment sites: head & neck, thorax, pelvis, abdomen, extremities.
Clinical Trial #: UPCC 23309
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

Pediatric Proton Consortium Registry (PPCR)

Study: A multi-center registry of pediatric patients treated with proton radiation therapy.
Clinical Trial #: 12-103
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Rare Tumors

Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Clinical Trial #: S1609
Principal Investigator: Christopher George, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Registry

Study: Evaluation tracking project: a prospective chart review of patients treated with proton therapy.
Clinical Trial #: REG001-09
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

Cross-disease sites

Study: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Clinical Trial #: MTG
Principal Investigator: Dr. Abad

Study: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Clinical Trial #: S2104
NCT #: NCT05040360
Principal Investigator: Dr. Mulcahy
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Clinical Trial #: A021806
NCT Number: NCT04340141
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
Clinical Trial #: PAN009-18
NCT Number: NCT02598349
Principal Investigator: Dr. Mohammed
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Evaluating the Response to Neoadjuvant Chemotherapy with Circulating Tumor DNA in Pancreatic Cancer
Clinical Trial #: ctDNA
NCT Number: NCT04616131
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Clinical Trial #: EA2186
NCT Number: NCT04233866
Principal Investigator: Kevin Dawravoo, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Clinical Trial #: EA2185
NCT Number: NCT04239573
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM
Clinical Trial #: A032101
NCT #: NCT05241860
Principal Investigator: Dr. Fenton
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
Clinical Trial #: PCG-GU010-18
NCT #: NCT00969111
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Clinical Trial #: NRG-GU009
NCT#: NCT04513717
Principal Investigator: Dr. Sean Sachdev
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Phase III Study of Image Guided Radiation Therapy with or without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
Clinical Trial #: GU003-10
NCT#: NCT01492972
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
Clinical Trial #: NRG-GU010
NCT#: NCT05050084
Principal Investigator: Sean Sachdev
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Clinical Trial #: EA8191
NCT#: NCT04423211
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes (PROMISE)
Clinical Trial #: C19-235
NCT #: NCT04995198
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281)
NCT #: NCT04493853
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Clinical Trial #: PARTIQoL
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: (IRONMAN) International Registry for Men with Advanced Prostate Cancer.
Clinical Trial #: c16-170
NCT Number: NCT03151629
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Clinical Trial #: S2015
Principal Investigator: Dr. Wayne
Contact: Research Office 630.933.7820

Endometrial

Study: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer
Clinical Trial #: NRG-GY012
NCT #: NCT03660826
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Endometrial

Study: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Clinical Trial #: GY018
NCT #: NCT03914612
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Endometrial

Study: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Clinical Trial #: NRG-GY026
NCT #: NCt05256225
Principal Investigator: Emily Hinchcliff
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian

Study: A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Clinical Trial #: NRG-GY023 / 22-013
NCT #: NCT04739800
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian

Study: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Clinical Trial #: NRG-CC008
NCT #: NCT04251052
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian or Peritoneum

Study: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Clinical Trial #: NRG-GY019
NCT Number: NCT04095364
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Current Northwestern Medicine Proton Center Clinical Trials

If you are interested in learning more about our trials, please contact your physician or visit the proton center website. If you are eligible for a proton therapy clinical trial as a patient at the Proton Center, someone from our team will likely reach out to you to communicate the details of the study.